XE9.F Xencor Inc
- Market cap
- EUR 2.64B
- P/E
- -
- P/B
- 5.26x
- ROE
- -26.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is XE9.F undervalued?
Graham numberThe Graham number of Xencor Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Xencor Inc fundamental analysis
No fundamental analysis for Xencor Inc yet.
Xencor Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispec…
Full company profileXencor Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Xencor Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 87.5M | 35.7M | 40.6M | 157M | 123M | 275M | 165M | 175M | 110M | 126M | 230M |
| Gross Profit | 57.1M | -25.6M | -56.9M | 38.1M | - | - | - | - | - | - | - |
| Operating Income | 22.5M | -53.6M | -79.4M | 13.8M | -76.8M | 43.8M | -82.5M | -132M | -178M | -178M | -123M |
| EBITDA | - | -47.3M | -67.1M | 18.1M | -71.0M | - | -45.7M | -102M | -186M | -47.2M | -117M |
| Net Income | 23.6M | -48.9M | -70.4M | 26.9M | -69.3M | 82.6M | -55.2M | -133M | -233M | -91.9M | -148M |
| EPS | - | -1.04 | -1.25 | 0.47 | -1.20 | 1.41 | -0.92 | -2.18 | -3.32 | -1.28 | -1.98 |
| Balance Sheet | |||||||||||
| Total Assets | 429M | 390M | 577M | 670M | 703M | 838M | 846M | 953M | 952M | 875M | 771M |
| Total Liabilities | 115M | 108M | 55.1M | 77.0M | 131M | 105M | 119M | 284M | 278M | 240M | 210M |
| Shareholders' Equity | 314M | 282M | 522M | 593M | 572M | 734M | 727M | 669M | 678M | 636M | 560M |
| Cash & Short-term Investments | 14.5M | 16.5M | 26.2M | 50.3M | 164M | 143M | 53.9M | 53.8M | 40.9M | 54.1M | 59.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 95.2M | -33.6M | -79.8M | 64.4M | -5.00M | -16.9M | 24.5M | -77.9M | -202M | -135M | -161M |
| Capital Expenditure | 3.01M | 5.31M | 7.21M | 7.35M | 10.5M | 13.3M | 38.5M | 21.3M | 9.51M | 3.15M | 3.94M |
| Free Cash Flow | - | -41.0M | -88.9M | 53.3M | -18.8M | -32.8M | -18.9M | -99.2M | -212M | -138M | -165M |
| Ratios | |||||||||||
| ROE | 7.5% | -17.3% | -13.5% | 4.5% | -12.1% | 11.3% | -7.6% | -19.9% | -34.3% | -14.5% | -26.5% |
| ROA | 5.5% | -12.5% | -12.2% | 4.0% | -9.9% | 9.9% | -6.5% | -14.0% | -24.4% | -10.5% | -19.2% |
| Net Profit Margin | 27.0% | -137.0% | -173.4% | 17.2% | -56.5% | 30.0% | -33.5% | -76.2% | -210.5% | -73.2% | -64.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Xencor Inc dividends
Xencor Inc has not paid dividends in the last 9 fiscal years.
Who owns Xencor Inc
- Insiders 1.21%
- Institutions 98.79%
- Public & others 0.00%
- Shares outstanding 75.0M
- Free float 54.9M
Xencor Inc company profile
- Company name
- Xencor Inc
- Ticker
- XE9.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 260
- Fiscal year end
- December
- Address
- 465 North Halstead Street, Pasadena, CA, United States, 91107
- Phone
- 626 305 5900
- Website
- xencor.com
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Xencor Inc management
10- Dr. Bassil I. Dahiyat Ph.D.Co-Founder, CEO, President & Director · born 1970
- Mr. Bart Jan CornelissenSenior VP & CFO · born 1978
- Dr. John R. Desjarlais Ph.D.Executive VP of Research & Chief Scientific Officer · born 1964
- Ms. Celia E. Eckert J.D.Senior VP, General Counsel & Corporate Secretary · born 1972
- Mr. Charles LilesAssociate Director and Head of Corporate Communications & Investor Relations
- Ms. Jennifer SandozSenior VIce President of Human Resources
- Mr. Eric P. KowackSenior Vice President of Program Leadership & Alliance Management
- Mr. Dane Vincent Leone C.F.A.Executive VP & Chief Strategy Officer
- Dr. Mark Osterman M.D.Senior Vice President of Clinical Development (Autoimmune)
- Dr. Jeffrey Chou M.D., Ph.D.Senior Vice President of Clinical Development- Oncology